Plegridy, also known as peginterferon beta 1a, is a medication used to treat relapsing remitting multiple sclerosis (MS).
How Plegridy Works
Plegridy is classified as a disease-modifying drug (DMD). Here's a breakdown of its function:
- Target: Plegridy is specifically designed to manage relapsing remitting MS.
- Mechanism: It works by reducing the frequency and intensity of MS relapses.
- Administration: It's self-administered through subcutaneous injections (under the skin) once every two weeks.
Benefits of Using Plegridy
- Reduced Relapse Rate: Clinical data indicates that Plegridy can decrease the number of relapses by approximately one-third (30%).
- Slower Disease Progression: By managing relapses, Plegridy helps slow down the progression of MS.
- Improved Quality of Life: Reduced relapses can significantly enhance the day-to-day well-being of individuals with relapsing remitting MS.
Important Considerations
- Dosage: Plegridy is administered through self-injections every two weeks.
- Professional Guidance: Always follow the guidance of your healthcare provider when using Plegridy.
- Side Effects: Be aware of possible side effects and report any concerns to your doctor.
Feature | Description |
---|---|
Drug Name | Peginterferon beta 1a (Plegridy) |
Condition | Relapsing remitting Multiple Sclerosis (MS) |
Type | Disease modifying drug (DMD) |
Administration | Self-administered via subcutaneous injection every two weeks |
Effect | Reduces relapse frequency and severity by about 30% |